Showing 1-12 of 12 Results
Jin Billy Li
Associate Professor of Genetics
Current Research and Scholarly InterestsThe Li Lab is primarily interested in RNA editing mediated by ADAR enzymes. We co-discovered that the major function of RNA editing is to label endogenous dsRNAs as "self" to avoid being recognized as "non-self" by MDA5, a host innate immune dsRNA sensor, leading us to pursue therapeutic applications in cancer, autoimmune diseases, and viral infection. The other major direction of the lab is to develop technologies to harness endogenous ADAR enzymes for site-specific transcriptome engineering.
Associate Professor of Biochemistry
BioDr. Li is an associate professor in the Biochemistry Department and ChEM-H Institute at Stanford since 2015. Her lab works on understanding biochemical mechanisms of innate immunity and harnessing it to treat cancer. She majored in chemistry at University of Science and Technology of China and graduated with a B. En in 2003. She then trained with Dr. Laura Kiessling, a pioneer in chemical biology, at University of Wisconsin-Madison and graduated with a Ph.D in chemistry in 2010. She obtained her postdoctoral training with Dr. Timothy Mitchison at Harvard Medical School, who introduced her to the field of chemical immunology.
Associate Professor of Neurobiology, of Bioengineering and, by courtesy, of Chemical and Systems Biology
Current Research and Scholarly InterestsOur lab applies biochemical and engineering principles to the development of protein-based tools for investigating biology in living animals. Topics of investigation include fluorescent protein-based voltage indicators, synthetic light-controllable proteins, bioluminescent reporters, and applications to studying animal models of disease.
Assistant Professor of Developmental Biology (Stem Cell)
BioHow the richly varied cell-types in the human body arise from one embryonic cell is a biological marvel and mystery. We have mapped how human embryonic stem cells develop into over twenty different human cell-types. This roadmap allowed us to generate enriched populations of human liver, bone, heart and blood vessel precursors in a Petri dish from embryonic stem cells. Each of these tissue precursors could regenerate their cognate tissue upon injection into respective mouse models, with relevance to regenerative medicine. In addition to our interests in developmental and stem cell biology, we also interested in discovering the entry receptors and target cells of deadly biosafety level 4 viruses, together with our collaborators.
Kyle attended the County College of Morris and Rutgers University, and received his Ph.D. from Stanford University (working with Irving Weissman), with fellowships from the Hertz Foundation, National Science Foundation and Davidson Institute of Talent Development. He then continued as a Siebel Investigator, and later, as an Assistant Professor and The Anthony DiGenova Endowed Faculty Scholar at Stanford, where he is jointly appointed in the Department of Developmental Biology and Institute for Stem Cell Biology & Regenerative Medicine. Kyle is a Packard Fellow, Pew Scholar, Human Frontier Science Program Young Investigator and Baxter Foundation Faculty Scholar, and his research has been recognized by the NIH Director's Early Independence Award, Forbes 30 Under 30, Harold Weintraub Graduate Award, Hertz Foundation Thesis Prize and A*STAR Investigatorship.
Jonathan Z. Long
Assistant Professor of Pathology
BioDr. Jonathan Long is an Assistant Professor of Pathology and an Institute Scholar of Stanford ChEM-H (Chemistry, Engineering & Medicine for Human Health). Prior to arriving to Stanford in 2018, Dr. Long completed his Ph.D. in Chemistry at Scripps Research with Benjamin F. Cravatt and his postdoctoral work at Harvard Medical School/Dana-Farber Cancer Institute with Bruce M. Spiegelman. His contributions in the areas of lipid biochemistry and energy homeostasis have been recognized by numerous awards from the National Institutes of Health and the American Diabetes Association. At Stanford, the Long laboratory studies signaling pathways in mammalian energy metabolism. The long-term goal of this work is to discover new molecules and pathways that can be translated into therapeutic opportunities for obesity, metabolic disease, and other age-associated chronic diseases.
Sharon R. Long
William C. Steere, Jr. - Pfizer Inc. Professor of Biological Sciences and Professor, by courtesy, of Biochemistry
Current Research and Scholarly InterestsBiochemistry, genetics and cell biology of plant-bacterial symbiosis
Associate Professor of Medicine (Gastroenterology and Hepatology), Emeritus
Current Research and Scholarly InterestsThe laboratory is focused on the relationship between injury, wound healing, and cancer. Esophageal, gastric, and pancreatic cancers are a focus. We are particularly interested in the regulation of cell signaling by EGFR, the EGF receptor. In addition to cancer pathogenesis, active projects include the development of new diagnostic assays and drugs.
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is a hematologist and medical oncologist in the Division of Hematology, Department of Medicine, studying novel therapeutics for challenging cancers and immune disorders.
Sydney's research career started with graduate studies in the laboratory of Dr. Marcel van den Brink at Memorial Sloan Kettering Cancer Center (MSKCC) studying the biology of pathologic donor T cells during graft-versus-host-disease and beneficial T cells mediating graft-versus-tumor effects after allogeneic bone marrow transplant, as well as the role of the thymus in regenerating healthy and protective donor-derived T cells post-transplant.
The direct relevance of these cellular therapies and their immediate translational applicability to patients inspired him to attend medical school at Stanford and further training in hematology and medical oncology at Memorial Sloan Kettering. There, as a fellow and junior faculty member, he studied disordered RNA splicing in cancer in the laboratory of Dr. Omar Abdel-Wahab, with the goal of developing novel drugs targeting RNA splicing. This work has led to observations that targeted degradation of the RNA binding protein RBM39 may be a feasible therapeutic for the treatment of myeloid cancers bearing RNA splicing factor mutations and that pharmacologic RNA splicing inhibition can generate MHC I-presented peptide neoantigens which are exploitable for immunotherapy in model systems.
Sydney's laboratory is broadly interested in studying RNA processing and splicing in the contexts of:
1) normal and pathologic immunity and immunotherapy
2) cancer biology
3) normal and malignant hematopoiesis
Ann and Bill Swindells Professor and Professor, by courtesy, of Neurobiology
Current Research and Scholarly InterestsWe study how neurons are organized into specialized circuits to perform specific functions and how these circuits are assembled during development. We have developed molecular-genetic and viral tools, and are combining them with transcriptomic, proteomic, physiological, and behavioral approaches to study these problems. Topics include: 1) assembly of the fly olfactory circuit; 2) assembly of neural circuits in the mouse brain; 3) organization and function of neural circuits; 4) Tool development.